(RTTNews) - Omeros Corp. (OMER), a clinical-stage biopharmaceutical company focused on complement-mediated diseases, oncology, and addictive disorders, today announced its financial results for the ...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in Blood Advances, a journal of the American Society of Hematology, detailing ...
ABSTRACT: LGALS1 is a protein belonging to the lectin family, widely distributed across immune and non-immune tissues. Characterized by high evolutionary conservation, LGALS1 specifically binds ...
ABSTRACT: LGALS1 is a protein belonging to the lectin family, widely distributed across immune and non-immune tissues. Characterized by high evolutionary conservation, LGALS1 specifically binds ...
Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...
Omeros (OMER) announced that an independent statistical group has completed the primary statistical analysis agreed with the FDA for narsoplimab, Omeros’ first-in-class monoclonal antibody inhibiting ...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that two abstracts directed to zaltenibart (OMS906), Omeros’ investigational inhibitor of MASP-3, the key activator of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback